Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis

Expert Opinion on Drug Delivery

Volumn 11, Issue 5, 2014, Pages 633-646

  Khatik, Renuka ^a   Dwivedi, Pankaj ^a   Khare, Prashant ^a   Kansal, Shaswat ^a   Dube, Anuradha ^a   Mishra, Prabhat Ranjan ^a   Dwivedi, Anil Kumar ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Amastigotes; Gelatin nanoparticles; J774A.1 cell lines; Leishmania donovani; Phosphatidylserine

Indexed keywords

1,2 DIACYL SN GLYCERO 3 PHOSPH LEVO SERINE; AMPHOTERICIN B; GELATIN; NANOPARTICLE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; MACROPHAGE; NONHUMAN; ORGAN DISTRIBUTION; RAT; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; COATED MATERIALS, BIOCOMPATIBLE; CRICETINAE; DRUG CARRIERS; FLOW CYTOMETRY; GELATIN; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MACROPHAGES; MALE; MESOCRICETUS; MICROSCOPY, CONFOCAL; NANOPARTICLES; NITRIC OXIDE; PARTICLE SIZE; PHOSPHATIDYLSERINES; RATS; RATS, WISTAR; SPLEEN;

EID: 84899097691     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.889678     Document Type: Article

References (62)

1. Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health StatQ1992;45(2-3):267-75
2. Murray HW, Berman JD, Davies CR, et al. Advances in leishmaniasis. Lancet 2005;366(9496):1561-77 (Pubitemid 41540115)
3. Medrano FJ, Canavate C, Leal M, et al. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type-1. Am J Trop Med Hyg 1998;59:155-62 (Pubitemid 28304814)
4. Rosenthal E, Marty P, Poizot-Martin I, et al. Visceral leishmaniasis and HIV-1 co-infection in southern france. Trans R Soc Trop Med Hyg 1995;89(2):159-62
5. Bora D. Epidemiology of visceral leishmaniasis in india. Natl Med J India 1999;12(2):62-8
6. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008;21(2):334-59 (Pubitemid 351555511)
7. Vyas SP, Quraishi S, Gupta S, et al. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005;296(1-2):12-25 (Pubitemid 40693368)
8. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect 2008;4:25-36
9. Torrado JJ, Espada R, Ballesteros MP, et al. Amphotericin B formulations and drug targeting. J Pharm Sci 2008;97(7):2405-25
10. Banerjee G, Nandi G, Mahato SB, et al. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother 1996;38:145-50 (Pubitemid 126449219)
11. Baillie AJ, Coombs GH, Dolan TF, et al. Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate. J Pharm Pharmacol 1987;39(10):832-5 (Pubitemid 18012993)
12. Paul M, Durand R, Fessi H, et al. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob Agents Chemother 1997;41(8):1731-4 (Pubitemid 27339876)
13. Paul M, Durand R, Boulard Y, et al. Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J Drug Target 1998;5(6):481-90 (Pubitemid 28499682)
14. Kopecek J, Kopeckova P, Minko T, et al. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000;50:61-81 (Pubitemid 30326689)
15. Venier-Julienne MC, Benoit JP. Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm Acta Helv 1996;71(2):121-8 (Pubitemid 26281321)
16. Espuelas MS, Legrand P, Campanero MA, et al. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother 2003;52(3):419-27 (Pubitemid 37120721)
17. Chawla JS, Amiji MM. Biodegradable poly("-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 2002;249(1-2):127-38 (Pubitemid 35333439)
18. Tiyaboonchai W, Limpeanchob N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm 2007;329(1-2):142-9 (Pubitemid 44937518)
19. Narayani R, Rao KP. Controlled release of anticancer drug methotrexate from biodegradable gelatin microspheres. J Microencapsul 1994;11:69-77 (Pubitemid 24030964)
20. Cascone MG, Lazzeri L, Carmignani C, et al. Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate. J Mater Sci Mater Med 2002;13(5):523-6 (Pubitemid 34454486)
21. Leo E, Angela Vandelli M, Cameroni R, et al. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involvement of the drug in the crosslinking process. Int J Pharm 1997;155:75-82 (Pubitemid 27368124)
22. Verma AK, Sachin K, Saxena A, et al. Release kinetics from bio-polymeric nanoparticles encapsulating protein synthesis inhibitor- cycloheximide, for possible therapeutic applications. Curr Pharm Biotechnol 2005;6(2):121-30 (Pubitemid 40637385)
23. Yeh TK, Lu Z, Wientjes MG, et al. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 2005;22(6):867-74 (Pubitemid 40898096)
24. Bajpai AK, Choubey J. Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate. J Mater Sci Mater Med 2006;17(4):345-58
25. Sham JO, Zhang Y, Finlay WH, et al. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 2004;269(2):457-67 (Pubitemid 38045308)
26. Truong-Le VL, Walsh SM, Schweibert E, et al. Gene transfer by DNA-gelatin nanospheres. Arch Biochem Biophys 1999;361:47-56 (Pubitemid 29393713)
27. Kaul G, Amiji M. Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles. J Pharm Sci 2005;94:184-98 (Pubitemid 40116382)
28. Kaul G, Amiji M. Tumor-targeted gene delivery using poly(ethylene glycol)- modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res 2005;22(6):951-61 (Pubitemid 40898105)
29. Balthasar S, Michaelis K, Dinauer N, et al. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 2005;26(15):2723-32 (Pubitemid 39600725)
30. Dinauer N, Balthasar S, Weber C, et al. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 2005;26(29):5898-906 (Pubitemid 40803459)
31. Li JK, Wang N, Wu XS. Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method. J Microencapsul 1998;15(2):163-72 (Pubitemid 28105132)
32. de Freitas Balanco JM, Moreira ME, Bonomo A, et al. Apoptotic mimicry by an obligate intracellular parasite downregulates macrophage microbicidal activity. Curr Biol 2001;11(23):1870-3 (Pubitemid 33136527)
33. Fadok VA, de Cathelineau A Daleke DL, et al. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem 2001;276(2):1071-7 (Pubitemid 32096530)
34. Fadok VA, Bratton DL, Frasch SC, et al. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ 1998;5(7):551-62 (Pubitemid 28356576)
35. Dhaliwal BS, Steinbrecher UP. Scavenger receptors and oxidized low density lipoproteins. Clin Chim Acta 1999;286(1-2):191-205 (Pubitemid 29406108)
36. Freire-de-Lima CG, Nascimento DO, Soares MB, et al. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 2000;403(6766):199-203 (Pubitemid 30050963)
37. Nishikawa K, Arai H, Inoue K. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J Biol Chem 1990;265(9):5226-31
38. Rigotti A, Acton SL, Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 1995;270(27):16221-4
39. Yamaguchi A, Yamamoto N, Akamatsu N, et al. PS-liposome and ox-LDL bind to different sites of the immunodominant domain (#155-183) of CD36: a study with GS95, a new anti- CD36 monoclonal antibody. Thromb Res 2000;97(5):317-26 (Pubitemid 30089036)
40. van der Laan LJ, Dopp EA, Haworth R, et al. Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J Immunol 1999;162(2):939-47 (Pubitemid 29035419)
41. Coester CJ, Langer K, van Briesen H, et al. Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. J Microencapsul 2000;17(2):187-93 (Pubitemid 30135796)
42. Dwivedi P, Kansal S, Sharma M, et al. Exploiting 4-sulphate N-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro and in vivo. J Drug Target 2012;20(10):883-96
43. Leo E, Cameroni R, Forni F. Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates. Int J Pharm 1999;180:23-30 (Pubitemid 29131439)
44. Duverger A, Jackson RJ, van Ginkel FW, et al. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 2006;176(3):1776-83 (Pubitemid 43134322)
45. Coester C, Nayyar P, Samuel J. In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation. Eur J Pharm Biopharm 2006;62(3):306-14 (Pubitemid 43356580)
46. Kole L, Sakar K, Mahato SB, et al. Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis. Biochem Biophys Res Commun 1994;200:351-8 (Pubitemid 24183614)
47. Pal R, Anuradha Rizvi SY, et al. Leishmania donovani in hamsters: stimulation of non-specific resistance by some novel glycopeptides and impact on therapeutic efficacy. Experientia 1991;47(5):486-90
48. Garg R, Gupta SK, Tripathi P, et al. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin Exp Immunol 2005;140:149-56 (Pubitemid 40461084)
49. Dube A, Singh N, Sundar S. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 2005;96(4):216-23 (Pubitemid 40933669)
50. Berman JD, Hanson WL, Chapman WL, et al. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother 1986;30(6):847-51 (Pubitemid 17209135)
51. Guru PY, Agrawal AK, Singha UK, et al. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett 1989;245(1-2):204-8 (Pubitemid 19076232)
52. Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target 2007;15(6):437-44 (Pubitemid 47073059)
53. Wang J-J, Sung KC, Hu OY-P, et al. Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. J Control Release 2006;115(2):140-9 (Pubitemid 44559707)
54. Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006;43(7):917-24 (Pubitemid 44435523)
55. Saraogi GK, Sharma B, Joshi B, et al. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target 2011;19(3):219-27
56. Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307:93-102 (Pubitemid 41773257)
57. Wasan EK, Bartlett K, Gershkovich P, et al. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm 2009;372(1-2):76-84
58. Nagata K, Ohashi K, Nakano T, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996;271(47):30022-7 (Pubitemid 26389640)
59. Anderson HA, Maylock CA, Williams JA, et al. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003;4:87-91 (Pubitemid 36113217)
60. Kole L, Das L, Das PK. Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. J Infect Dis 1999;180(3):811-20 (Pubitemid 29411368)
61. Park D, Tosello-Trampont AC, Elliott MR, et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 2007;450(7168):430-4 (Pubitemid 350126756)
62. Kansal S, Tandon R, Dwivedi P, et al. Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis. J Antimicrob Chemother 2012;67(11):2650-60